Jovan-Embiricos Morana
Known title: 10% OwnerCIK: 0001575745
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Cullinan delays arthritis data update to December. Cullinan Therapeutics announced it will delay its arthritis data update for zipalertinib to December due to ongoing safety concerns. This decision follows the release of strong Phase 3 lung cancer data, which initially saw the stock drop 18.2%. The company also confirmed plans for Q4 2026 updates across three T cell engager programs.
Transaction History
| KLRS | ▲ Buy | Grant | 35,000 | $0 | 6/6/2024 | View on chart |
| KLRS | ▲ Buy | Grant | 35,000 | $0 | 5/11/2023 | View on chart |
| KLRS | ▲ Buy | Grant | 684,622 | $3.2M | 7/28/2022 | View on chart |
| KLRS | ▲ Buy | Grant | 325,379 | $1.5M | 7/28/2022 | View on chart |
| KLRS | ▲ Buy | Grant | 1,626,898 | $7.5M | 7/28/2022 | View on chart |
| KLRS | ▲ Buy | Grant | 1,393,874 | $6.4M | 7/28/2022 | View on chart |
| KLRS | ▲ Buy | Grant | 867,678 | $4.0M | 7/28/2022 | View on chart |
| KLRS | ▲ Buy | Grant | 3,253,796 | $15.0M | 7/28/2022 | View on chart |
| CGEM | ▲ Buy | Option Exercise | 104,845 | $451K | 6/24/2022 | View on chart |
| CGEM | ▲ Buy | Option Exercise | 35,529 | $153K | 6/24/2022 | View on chart |
| CGEM | ▼ Sell | Tax Withholding | 45,078 | $604K | 6/24/2022 | View on chart |
| KLRS | ▼ Sell | Open Market | 680 | $17K | 11/10/2021 | View on chart |
| KLRS | ▼ Sell | Open Market | 120 | $3K | 11/10/2021 | View on chart |
| KLRS | ▼ Sell | Open Market | 572 | $14K | 11/9/2021 | View on chart |
| KLRS | ▼ Sell | Open Market | 3,243 | $80K | 11/9/2021 | View on chart |
| KLRS | ▼ Sell | Open Market | 1,257 | $31K | 11/5/2021 | View on chart |
| KLRS | ▼ Sell | Open Market | 7,124 | $177K | 11/5/2021 | View on chart |
| KLRS | ▼ Sell | Open Market | 1,870 | $46K | 10/27/2021 | View on chart |
| KLRS | ▼ Sell | Open Market | 330 | $8K | 10/27/2021 | View on chart |
| KLRS | ▼ Sell | Open Market | 1,165 | $29K | 10/25/2021 | View on chart |
| KLRS | ▼ Sell | Open Market | 6,604 | $164K | 10/25/2021 | View on chart |
| KLRS | ▼ Sell | Open Market | 859 | $21K | 10/22/2021 | View on chart |
| KLRS | ▼ Sell | Open Market | 4,864 | $120K | 10/22/2021 | View on chart |
| KLRS | ▼ Sell | Open Market | 15 | $371 | 10/21/2021 | View on chart |
| KLRS | ▼ Sell | Open Market | 85 | $2K | 10/21/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Kalaris Therapeutics Moves in Pre-Market Amid Low RSI
Kalaris Therapeutics was highlighted in a roundup of health care stocks moving in Wednesday's pre-market session. The stock is currently trading near its 52-week low, with the RSI indicating oversold conditions. Analysts maintain a wide range of price targets for the company, reflecting varying views on its future performance.
Kalaris Therapeutics Moves in Pre-Market Amid Low RSI. Kalaris Therapeutics was highlighted in a roundup of health care stocks moving in Wednesday's pre-market session. The stock is currently trading near its 52-week low, with the RSI indicating oversold conditions. Analysts maintain a wide range of price targets for the company, reflecting varying views on its future performance.